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Abstract
Background: Used alone, the MAS5.0 algorithm for generating expression summaries has been
criticized for high False Positive rates resulting from exaggerated variance at low intensities.
Results: Here we show, with replicated cell line data, that, when used alongside detection calls,
MAS5 can be both selective and sensitive. A set of differentially expressed transcripts were
identified that were found to be changing by MAS5, but unchanging by RMA and GCRMA.
Subsequent analysis by real time PCR confirmed these changes. In addition, with the Latin square
datasets often used to assess expression summary algorithms, filtered MAS5.0 was found to have
performance approaching that of its peers.
Conclusion: When used alongside detection calls, MAS5 is a sensitive and selective algorithm for
identifying differentially expressed genes.
Background
A significant challenge with Affymetrix expression data is
to provide an algorithm that combines the signals from
the multiple Perfect-Match (PM) and Mismatch (MM)
probes that target each transcript into a single value that
sensitively and accurately represents its concentration.
MAS5.0 does this by calculating a robust average of the
(logged) PM-MM values [1]; increased variation is
observed at low signal strengths and is at least in part due
to the extra noise generated by subtracting the MM values
from their PM partners [2].
A number of alternatives (e.g. RMA [3]) have been pro-
posed that ignore the MM values, and consequently do
not suffer from this source of variation. RMA successfully
reduces the variance of low abundance transcripts and has
been shown, using controlled datasets in which known
quantities of specific mRNAs have been added to a com-
mon reference pool, to better distinguish differentially
expressed transcripts from those that are unchanging [2-
4]. In these experiments, only a small number of spikes
were added, with the consequence that the vast majority
of transcripts do not vary in concentration across the
arrays, and that the MM signal, which results from the
combined action of many weak, partial cross-hybridiza-
tions, might be expected to remain approximately con-
stant [5]. However, whilst MM probes may not have a
significant effect in 'spike-in' datasets such as these, they
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may be more useful with real experimental data, in which
many more transcripts are changing. In a recent study, sets
of 100–200 mRNAs were spiked into a known back-
ground set containing 2,551 different RNA species [5].
The authors found the MM probes to be of significantly
more utility, and that MM probe subtraction as performed
by MAS5.0 was the best background correction method of
the algorithms on test. See also [6] for further considera-
tion of these data. A variant of RMA, GCRMA [7,8], uses
intensity-summaries generated across sets of probes to
estimate non specific binding. The rationale is that
hybridization signal (and therefore probe intensity)
should at least in part be determined by binding effi-
ciency. Irrespective of the way different algorithms calcu-
late background, the consequences of a non-varying
signal should still apply; Choe et al. found that the
MAS5.0 MM subtraction outperformed the summary-
approach of GCRMA on their dataset [5].
Detection calls
In addition to expression summaries, the Affymetrix soft-
ware also generates a p-score that assesses the reliability of
each expression level. This is produced by using a signed
rank test to consider the significance of the difference
between the PM and MM values for each probeset [9].
Informally, MAS 5.0 can be seen to return two values, the
first, an estimate of transcript concentration, and the sec-
ond, a measure of how much the software 'believes' the
first. Of potential confusion is the fact that this value is
referred to as the 'detection p-value', and is subsequently
used to generate a 'detection call', which flags the tran-
script as 'Present', 'Marginal' or 'Absent' (P/M/A). In fact,
the detection p-value is closer to a reliability score – and
the terms 'Reliable', 'Marginal' and 'Unreliable' might be
more appropriate. The original approach to data analysis,
proposed by the manufacturer, was to use the MAS5.0
expression summary to provide an estimate of transcript
concentration, alongside detection calls to filter out unre-
liable probesets. Despite the fact that the expression sum-
mary algorithm has been shown to perform poorly on the
test datasets described above, many researchers have con-
tinued to use this combined strategy to process their data.
Shippy et al., for example, [10,11], use detection calls to
eliminate unreliable data in a comparison between differ-
ent array platforms and algorithms.
In the light of these recent findings, it is timely to revisit
the performance of MAS5.0, paying particular attention to
the use of detection calls. This paper describes a real-time
PCR study designed to consider the differences between
RMA, GCRMA and MAS5.0, with and without detection
filtering, before revisiting the spike-in datasets described
above. RMA and GCRMA were chosen for the study since
they are widely used within the community and their
behaviour is generally well understood. Comparing MAS5
to RMA allows it to be placed in context alongside other
algorithms.
Results
Differential expression in replicated cell lines
Figure 1 shows a comparison of the fold changes found
using MAS5.0 and RMA between triplicate samples taken
from two cell lines: the human breast cancer cell line
MCF7, and the non-tumorigenic breast epithelial cell line,
MCF10A, which unlike MCF7, lacks tumorigenicity in
nude mice, three-dimensional growth in collagen, sponta-
neous- and anchorage-independent growth.
If both algorithms produced identical fold-changes, all
points would be expected to lie on the diagonal. It can be
seen that there is significant discrepancy between the fold
changes reported by both algorithms, but that the major-
ity of these variations are confined to probesets flagged
Absent on one or more arrays. When data are stratified by
detection call, it can be seen that for probesets flagged
Present in all samples from both cell lines (PP), RMA and
MAS5.0 report similar fold changes. For probesets that are
flagged Absent on one or more arrays, there is disagree-
ment (i.e. PA or AA in the figure), with RMA tending to
report lower fold-changes than those found by MAS5.0.
The graphs are also asymmetric. There are no probesets
with high fold-changes according to RMA, but low fold-
changes according to MAS5.0. GCRMA produced very
similar results [additional file 1].
Figure 1 provides a qualitative overview of the data. Kappa
coefficients [12] can provide an additional metric for the
level of agreement between algorithms. Kappa is such that
for complete agreement, κ = 1, for chance levels of agree-
ment, κ = 0. With no stratification by detection call and a
two-fold threshold, κ = 0.42 between algorithms. When
analysis is restricted only to the PP probesets, agreement
is significantly increased; κ = 0.82.
Figure 1 draws a distinction between probesets flagged
Absent in both sets of samples (AA), and those flagged as
Absent in one cell line, Present in the other (PA). If data
are filtered using detection calls, then the AA probesets
would be eliminated from further consideration. For these
probesets, MAS5.0 and RMA are in agreement, except in
cases where the fold change from RMA is greater than
some significance threshold. Of the 29,998 (55%) AA
probesets in this experiment, less than 2% (395) have an
RMA fold change > 2. Thus RMA and MAS5.0 are in agree-
ment for almost all AA probesets. The PA probesets in the
figure represent those that are flagged as unreliable in one
cell line, reliable in the other, and can be considered to be
changing between being above and below the limit of
detection for the system. For these, RMA consistently
reports lower fold changes than MAS5.0 (1,522 of 6,296BMC Bioinformatics 2007, 8:273 http://www.biomedcentral.com/1471-2105/8/273
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probesets show at least a 2-fold lower fold change in RMA
than MAS5.0). Over 18% of these probesets (1,142 of
6,296) have a fold change less than 2-fold by RMA but
greater than 2-fold by MAS5.0.
Thus it can be seen that when data are stratified by detec-
tion call, only 1,522 + 395 = 1,917 probesets are called
differently by MAS5 and RMA when a two fold cutoff is
used for selection (κ = 0.80; RMA fold change > 2 vs.
MAS5 fold change >2 and PP or PA). Although they repre-
sent a small proportion of the entire array, these probesets
are of disproportionate interest because a substantial
number of them are flagged as changing from Present to
Absent by the detection calling algorithm, representing a
change in concentration from above to below the levels of
detection of the system. It is reasonable to consider the
possibility that some of them, at least, are changing from
'on' to 'off'. This is a crucial subset of the data because of
their potential to act as switches, invoking novel patterns
of activity of phenotype.
Validation by real time PCR
In order to further investigate the differences between
MAS5 and RMA, a set of probesets were selected for follow
up by real time PCR, which was used to provide an inde-
pendent estimate of the expected 'true' values [11].
Probesets were from taken from the PP, PA and AA sets,
partitioned by fold change and selected to cover a range of
fold changes (Methods; figure 2). Since the aim was to
investigate the similarities and differences in fold change
found by the different algorithms, data were stratified by
fold change, not by intensity. Thus, four sets of probesets
were considered: PP probesets that both RMA and MAS5
identified as changing, PA probesets (for which MAS5
reported a change and RMA reported small changes), AA
probesets for which MAS5 reported low confidence in the
data and RMA reported low fold change, and AA probesets
for which RMA reported a fold-change greater than two
(referred to here as 'AA-RMA' probesets). The 35 assays
presented here represent PP, PA, AA and AA-RMA
probesets across a range of fold changes. Figure 3 shows
that for the PP probesets, real time PCR confirms the dif-
ferential expression found using RMA, GCRMA and
MAS5.0 for all but one probeset (221874_at). Even
though the AA probesets were flagged as unreliable by
detection call, they still receive a fold change from all
three algorithms. All selected probesets had at least 4-fold
differential expression according to MAS5.0 and a low
fold change reported by RMA and GCRMA. In every case
except one (1552473_at), real time PCR found significant
fold changes in the same direction as that found by
MAS5.0.
Thus, for the 5 AA probesets tested, all three algorithms
correctly reported no change for one of the probes
(1552473_at), and failed to correctly call fold changes for
four of them (1552338_at, 1561881_at, 1563656_at, and
1568848_at). 395 probesets were found to have a >2 fold
change by RMA but were flagged AA by MAS5. (Interest-
ingly, 387 of them also had a fold change >2 reported by
MAS5). 13 of these were tested by real time PCR, which
found significant fold changes (i.e. greater than 2-fold),
over all three replicates, for 9 of them and low fold
changes for 1 (235201_at). For three assays (209618_at,
205258_at, 206482_at), real time PCR was unable to
detect any expression. Thus, real time PCR supported the
RMA and GCRMA data for 69% of the AA-RMA probesets.
Of the 1,522 PA probesets found to have less than 2-fold
change according to RMA, 8 were pursued further by real
time. For these, where GCRMA and RMA consistently
reports lower fold changes than MAS5.0, the MAS5.0 data
were supported by the real time PCR results in all 8 cases,
contradicting the changes reported by the other algo-
A comparison of fold changes found by RMA and MAS5 for MCF7 and MCF10a cell line data Figure 1
A comparison of fold changes found by RMA and MAS5 for MCF7 and MCF10a cell line data. Absent-flagged 
probesets show significant disagreement between the two algorithms. First panel: all data. Remaining panels are separated by 
detection calls. AA: probesets flagged Absent by MAS5 detection call. PA: probesets flagged Absent in one cell line, Present in 
the other. PP: probesets flagged Present in both cell lines. Lines represent 2-fold thresholds (data are on a log2 scale). Details 
of Present/Absent flagging can be found in Methods.BMC Bioinformatics 2007, 8:273 http://www.biomedcentral.com/1471-2105/8/273
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rithms. This is interesting not least because the detection
calls are identifying these probesets as having poor signal
to noise ratio for the Absent flagged data (see discussion).
It is useful to further quantify these results. One common
method is to use Pearson correlation to provide a similar-
ity metric. However, Pearson correlation (both centred
and uncentred) must be treated with caution when com-
paring fold-changes. In particular, because it standardizes
expression profiles, it is not appropriate if the actual mag-
nitude of the fold-change is important, rather than simply
the pattern of change across a set of samples. This is clearly
demonstrated by the uncentred Pearson correlations for
the MAS5 and RMA data, against the real time PCR results.
For the PA probesets in figure 2, r = 0.93 for MAS5, and
0.92 for RMA, even though RMA consistently reports
much lower fold-changes (max(fc): RMA = 0.92; MAS5 =
5.02; log2 scale). Correlation data for all subgroups can be
found in [see additional file 2].
An alternate metric is the concordance correlation coeffi-
cient [13], rc. It is similar to Pearson's correlation, but
measures not only the linear correlation between data
points, but also how well they match the identity line
[14]. Using rc, correlation is high for the PP probesets for
both algorithms: rc = 0.92 and 0.93 for MAS5 and RMA,
respectively. However, for the PA probesets, rc = 0.93 for
MAS5, and 0.32 for RMA, for the AA-RMA probesets rc =
0.67 for MAS5 and 0.47 for RMA, and for the AA
probesets, rc = 0.72 and 0.24, respectively. Thus the con-
cordance correlation coefficient successfully distinguishes
between the cases and provides a useful quantitative met-
ric when fold changes are of importance.
It is also useful to consider these data in terms of True- and
False- Positives and Negatives. In order to do this, a deci-
sion must be taken as to how to treat AA flagged data. For
the purposes of this analysis, AA flagged probesets that
targeted truly differentially expressed transcripts (as
defined by real time PCR) are simply considered to be
False Negatives. Similarly, AA probesets found to repre-
sent unchanging transcripts, or probesets targeting tran-
scripts that were undetectable by real time, are reported as
True Negatives. The data are summarized in table 1.
It can be seen that the both algorithms behave similarly
for the PP and AA probesets, and that the key source of
discrepancy is for the PA and AA-RMA sets. Over these
data, MAS5 made correct predictions for 100% of the PA
probesets, and 31% of the AA-RMA ones, while RMA was
correct for 0% of the PA probesets, and 69% of the AA-
RMA ones.
MA plots of the MAS5 and RMA processed data showing probesets selected for real time PCR Figure 2
MA plots of the MAS5 and RMA processed data showing probesets selected for real time PCR. Light grey points 
all data. Circles: PA probesets. Diagonal Crosses: AA-RMA probesets. Triangles: AA probesets. Vertical Crosses: PP 
probesets. RMA reports the fold change for the PA, AA and AA-RMA probesets as low in comparison to MAS5. AA and PA 
probesets are of low intensity. Additional MA plots, stratified by detection call can be found in the supplementary data.BMC Bioinformatics 2007, 8:273 http://www.biomedcentral.com/1471-2105/8/273
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Four of the 'truly changing' AA flagged probesets were
considered to be False Negatives. It is important to appre-
ciate that by flagging these probesets AA, the algorithm is
refraining from making a call rather than explicitly calling
the probeset as being unchanging (i.e., it is reporting
'don't know' rather than 'no-change'). Thus, although
MAS5 fails to make the right call for these data, by report-
ing 'don't know', it is not getting them wrong either. From
this perspective, counting AA probesets as either True- or
False-Negatives is a somewhat restrictive interpretation,
since doing so fails to recognize the algorithm's ability to
Comparison between fold changes from MAS5 and RMA and those found using real time PCR (rt1, rt2, rt3) Figure 3
Comparison between fold changes from MAS5 and RMA and those found using real time PCR (rt1, rt2, rt3). 
PA: Present-Absent probesets. PP: Present-Present probesets. AA: Absent-Absent probesets. AA-RMA: Absent-Absent 
probesets with fold changes > 2 according to RMA. Data are on a log2 scale.
Table 1: Correct and incorrect predictions for both algorithms
MAS5 (found/actual number by real time) RMA (found/actual number by real time)
TP FP TN FN TP FP TN FN
PP 8/8 1/1 0/0 0/0 8/8 1/1 0/0 0/0
PA 8/8 0/0 0/0 0/0 0/0 0/0 0/0 8/8
AARMA 0/0 0/0 4/4 9/9 9/9 4/4 0/0 0/0
AA 0/0 0/0 1/1 4/4 0/0 0/0 1/1 4/4
TP: True Positive. FP: False Positive. TN: True Negative. FN: False Negative. For example, for the PP set, MAS5 and RMA both found 8 TPs out of 
a total of 8 possible, and made 1 incorrect prediction, resulting in 1 FP.BMC Bioinformatics 2007, 8:273 http://www.biomedcentral.com/1471-2105/8/273
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avoid making a call when the data is not of sufficient qual-
ity to warrant it.
Latin square data revisited
The high performance of MAS5.0 on these data is perhaps
surprising, given that it has previously been reported to
perform badly on the Latin square datasets described
above [2-4]. Figures 4A and 4B show fold changes for
these data, processed using MAS5.0 and RMA, as found by
'affycomp' package in BioConductor [4]. Figure 4C shows
the results of filtering the MAS5.0 data by detection call
(see also Methods). Much of the low intensity variation is
eliminated, significantly reducing the number of False
Positives (FPs) and bringing the data closer into line with
RMA. This can be quantified using affycomp, a tool
designed to score the performance of expression summary
algorithms (on the spike-in datasets described above)
against a variety of criteria, and to use these scores to pro-
vide an unbiased assessment of their relative performance
[4]. Metrics are described in detail in [4,15], and are sum-
marized briefly in the methods. Of the 14 metrics
reported on the affycomp website, MAS5.0, when filtered
as described, marginally out-performs RMA on 6 of them
and comes close on a further 3 (table 2).
For these metrics its performance is similar to that of
GCRMA. For metrics dependent on accurate reporting of
fold change, MAS5.0 outperforms RMA, and is similar in
performance to GCRMA. 4 of the 14 metrics (low-, med-,
high- and weighted avg AUC) in affycomp are based on
ROC curves, generated by considering the number of True
Positives (TPs) for a given number of False Positive (FPs).
For these, it behaves worse than either RMA or GCRMA.
Investigation of individual TP and FP rates reveals that the
poor performance of MAS5.0 on the ROC based metrics is
due to a very high FP rate. Filtering by detection call, how-
ever, does lead to significant improvements: it successfully
reduces the number of FPs from 2,863 to 74 (figure 4).
When the algorithm is used alongside detection filtering
[16], its performance on these Latin square data becomes
much closer to that of its peers.
Thus, when filtered by detection call, MAS5.0 performs
well, not only on the spike-in datasets described above,
but also on real experimental data in which many tran-
scripts are differentially expressed. Further, MAS5.0, when
used alongside detection filtering correctly identifies a set
of differentially expressed transcripts for which other
approaches record low changes. As discussed earlier, these
PA probesets are of particular interest because of their
potential 'switching' behaviour.
Biological validation
In total, there are 40 PA probesets with greater than 8 fold
differential expression according to MAS5.0, but less than
2-fold by RMA (table 3), and 1,142 when the MAS5.0
threshold is reduced to 2-fold.
Space does not permit full consideration of every one;
instead we focus on those most highly over-expressed in
the MCF7 cells. L-threonine dehydrogenase (TDH) has
been identified as a transcribed pseudogene in humans
[17]. PTGER3 (EP3) has been shown to be involved in the
activation of Src signaling via Prostaglandin E2 (PGE2)
[18], and host stromal PGE2-EP3 signaling appears criti-
cal for tumor-associated angiogenesis and tumor growth
[19]. The MAS5.0 data shows PTGER3 to be upregulated
in MCF7 w.r.t. MCF10A. C5orf4 has been identified as a
putative tumour suppressor [20], whilst ZNF43 has been
shown, in vitro, using Ewing Sarcoma derived EW-1 cells,
to be highly expressed in proliferating cells and down reg-
ulated in cells induced to differentiate [21]. Treatment of
EW-1 cells with antisense oligonucleotides complemen-
tary to ZNF43 mRNA was shown to induce morphological
differentiation and growth arrest, suggesting a role for
ZNF43 in the maintenance of ES cells in an undifferenti-
ated state [21]. The MAS5.0 data shows ZNF43 to be over
expressed in MCF7 cells with respect to MCF10A. Over
expression of ZNF423 (OAZ) has been shown to lead to
elevated Smad6 expression in C2C12 cells [22]. Smad6 is
known to be an inhibitor of the BMP signalling pathway
and over expression of both OAZ and Smad6 have been
shown in pulmonary smooth muscle cells to result in
inhibition of BMP4 mediated apoptosis [22]. Both
ZNF423 and Smad6 are found to be over expressed in
MCF7 w.r.t. MCF10A, and both are flagged as being
Present in MCF7, Absent in MCF10A. Calcitonin receptor
expression has previously been reported in MCF7 cell
lines[23] and Wnt7B has been previously shown to be
upregulated in MCF7 [24]. Thus many of PA genes identi-
fied by MAS5.0 show behaviour in agreement with previ-
ous reports in the literature.
Discussion
When a simple fold-change threshold is used to define dif-
ferentially expressed genes, the MAS5.0 expression sum-
mary algorithm yields a significant number of false
positives, as illustrated in Figure 4B. This is, at least in part,
because even if the signal from both sets of replicates is
low, the resultant fold change can still be high. However,
as shown here, detection calls can be used to successfully
filter MAS5.0 data and remove the vast majority of false
positives. This is also in keeping with a recent study that
found a significant improvement in False Discovery Rate
following pre-filtering by detection call [25].
Detection calls also have significant utility when consider-
ing transcripts with expression levels close to the limits of
detection of the platform. By selecting probesets changing
consistently from Present to Absent, it is possible to iden-BMC Bioinformatics 2007, 8:273 http://www.biomedcentral.com/1471-2105/8/273
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tify a small but significant set of transcripts that have large
fold changes, are positively validated by real time PCR, are
consistent with previous reports in the literature, but are
not reported as changing by other approaches. Since
detection calls aim to identify probesets with poor signal
to noise ratio, it is reasonable to expect that the fold-
changes calculated for these probesets will be unreliable.
The relatively high degree of correspondence, for the PA
probesets, between the MAS5 data and the real time
results suggests that their signal to noise ratio is still high
enough to provide a relatively stable calculation of fold
change. The actual magnitude of fold changes calculated
using Absent flagged data should, however, be treated
MA plots for the Latin square data, generated by affycomp [4] Figure 4
MA plots for the Latin square data, generated by affycomp [4]. Points represent probesets targeting transcripts not 
expected to change, numbers represent probesets targeting transcripts spiked into the dataset at different concentration. The 
number represents the expected fold change. Fold change is represented by M on the y-axis. A: RMA processed data. B: Raw 
MAS5 processed data. C: filtered-MAS5 data. Raw MAS5 data suffers from a significant number of False Positives (i.e. probesets 
recording a differential expression greater than 2-fold), while RMA shows much better performance on these data. Filtering 
MAS5 data by detection call as described in Methods, significantly reduces the number of False Positives and brings the results 
much closer to those of RMA.
Table 2: Affycomp scores for RMA, GCRMA, MAS5 and MAS5 filtered by detection call
rma Gcrma mas5 filtered mas5
Median SD 0.07 0.06 0.29 0.08
null log-fc IQR 0.13 0.04 0.47 0.01
null log-fc 99.9% 0.40 0.61 4.01 1.25
Signal detect R2 0.90 0.91 0.91 0.88
Signal detect slope 0.68 1.00 0.77 0.77
low.slope 0.20 0.25 0.58 0.25
med.slope 0.71 1.13 0.73 0.79
high.slope 0.80 0.97 0.77 0.77
Obs-intended-fc slope 0.68 1.00 0.77 0.77
Obs-(low)int-fc slope 0.31 0.48 0.64 0.44
low AUC 0.43 0.35 0.00 0.19
med AUC 0.85 0.86 0.00 0.18
high AUC 0.93 0.86 0.00 0.18
weighted avg AUC 0.53 0.48 0.00 0.19
AFP, call if fc > 2 1.71 3.30 2863.36 73.73
ATP, call if fc > 2 32.91 35.40 35.45 34.18
FC = 2, AFP, call if fc > 2 0.24 1.95 2785.10 63.52
FC = 2, ATP, call if fc > 2 10.81 19.57 14.33 12.86
Metrics are described in detail in (Cope et al. 2003) and briefly in the methods. The last four rows record the number of True and False positives. 
Perfection for the first three rows is 0, and 1 for the next 11 rows. Filtering by detection call significantly improves the performance of MAS5 on 
the Latin square data.BMC Bioinformatics 2007, 8:273 http://www.biomedcentral.com/1471-2105/8/273
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with an appropriate degree of caution, and validation by
real time PCR is clearly advisable.
In the analyses of both the real time PCR and Latin square
datasets described above, probesets flagged AA were
treated in the same way as those that were found to be
unchanging. A consequence of this is that they were
reported as false negatives if subsequent validation found
their target transcripts to be differentially expressed. Since
the AA flag is better considered as a statement of uncer-
tainty rather than of no-change, this is a stringent interpre-
tation of the data. It is important therefore to note that
every real-time validated probesets for which MAS5 was
able to report a reliable change was positively confirmed;
where discrepancies arose they were restricted to AA
probesets for which, by definition, the algorithm was una-
ble to make a reliable call.
Irrespective of how false negatives are defined, no such
issues arise in the definition of true- and false-positives.
For these, both algorithms performed similarly, each cor-
rectly predicting changes for 8/9 of the PP probesets, and
both doing well on the PA and AA-RMA set (MAS5 was
correct for 100% of the PA probesets, RMA for 69% of the
AA-RMA probesets). Note that for both algorithms, the
probesets with the largest fold-changes were tested. The
Table 3: PA flagged probesets with > 8 fold differential expression according to MAS5 and less than 2 fold according to RMA.
Probeset ID f.c. ttest mcf7 mcf10a gene name
1553494_at 5.03 ± 0.59 0.00 4.05 -0.97 TDH
210833_at 4.69 ± 0.53 0.00 4.37 -0.32 PTGER3
1564699_at 4.56 ± 0.67 0.01 4.10 -0.46 C5orf4
222136_x_at 4.04 ± 0.54 0.00 7.62 3.58 ZNF43
1558687_a_at 3.86 ± 0.67 0.00 4.23 0.38 NA
228811_at 3.84 ± 0.56 0.00 4.33 0.48 PLA2G5
214761_at 3.59 ± 0.56 0.00 4.63 1.04 ZNF423
207886_s_at 3.58 ± 0.25 0.02 4.74 1.17 CALCR
217681_at 3.40 ± 1.28 0.00 5.66 2.26 WNT7B
210100_s_at 3.38 ± 0.98 0.00 6.48 3.11 ABCA2
205501_at 3.34 ± 1.23 0.04 3.58 0.25 NA
243580_at 3.29 ± 0.75 0.01 4.61 1.32 GNA14
214191_at 3.26 ± 0.68 0.00 5.07 1.81 ICA1
243650_at 3.20 ± 1.51 0.03 4.96 1.76 PLEKHH2
231795_at 3.19 ± 1.08 0.00 4.48 1.29 NA
230917_at 3.16 ± 1.19 0.03 4.34 1.18 NA
228090_at 3.13 ± 0.52 0.01 5.86 2.73 NMNAT3
216061_x_at 3.13 ± 0.63 0.00 6.35 3.22 PDGFB
243804_at 3.12 ± 0.57 0.01 4.12 1.00 FLJ32642
204778_x_at 3.09 ± 1.25 0.01 6.09 3.00 HOXB7
241744_x_at 3.08 ± 0.52 0.04 3.63 0.54 NA
226086_at 3.05 ± 0.49 0.00 4.18 1.13 SYT13
1569701_at 3.03 ± 0.47 0.04 3.91 0.89 PER3
225163_at 3.01 ± 0.72 0.01 5.05 2.03 FRMD4A
204885_s_at -3.22 ± 0.40 0.01 2.70 5.92 MSLN
214587_at -3.27 ± 0.28 0.03 0.64 3.92 COL8A1
233792_at -3.31 ± 0.61 0.00 0.51 3.82 NA
205964_at -3.44 ± 0.45 0.02 1.22 4.66 ZNF426
219983_at -3.47 ± 0.27 0.00 0.73 4.20 HRASLS
239955_at -3.47 ± 0.84 0.00 0.48 3.95 NA
1563693_at -3.50 ± 0.30 0.00 0.13 3.63 NA
1553574_at -3.59 ± 1.10 0.00 -0.20 3.39 IFNE1
219058_x_at -3.70 ± 1.22 0.01 2.46 6.16 LCN7
228821_at -3.75 ± 0.43 0.01 -0.17 3.58 ST6GAL2
1564796_at -3.87 ± 0.28 0.01 0.80 4.68 EMP1
225372_at -4.07 ± 0.39 0.00 0.74 4.82 C10orf54
1556773_at -4.14 ± 1.39 0.00 0.10 4.24 PTHLH
1562648_at -4.17 ± 0.84 0.00 0.10 4.28 KIAA1212
1558512_at -4.29 ± 1.38 0.00 -0.32 3.97 NA
1553654_at -4.45 ± 0.70 0.00 -0.97 3.48 SYT14
f.c.: log2 fold change, ± standard error. t-test: t-test p-score between replicates. MCF7, MCF10a: log2 mean expression level. Probesets marked in 
bold type were validated by real time PCR.BMC Bioinformatics 2007, 8:273 http://www.biomedcentral.com/1471-2105/8/273
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low-throughput nature of real time PCR meant that it was
not possible to systematically explore the entire AA-RMA
and PA subsets of the data, by, for example generating a
random sampling of these data and validating these by
real time. For this reason, it was not possible to define a
threshold below which reported changes were unreliable,
and attention must also be paid to the possibility that
regression towards the mean might have a certain influ-
ence on the correlation coefficients generated for each
algorithm [26]. What the study does show, however, is
that identifying PA probesets with large fold-changes is a
useful strategy for finding differentially expressed tran-
scripts that are not found by other approaches. Overall,
these data provide substantial support in favour of the use
of MAS5, filtered by detection call, as a rational alternative
for identifying differentially expressed transcripts from
Affymetrix microarray data.
Conclusion
The separation of the data into three sets (PP, PA and AA)
based on detection call offers an alternative strategy for
data analysis that has the potential to reveal additional
transcripts, within the PA category, that the other
approaches do not find. If a relatively high False Positive
rate is acceptable (~30% in this experiment) then it also
appears reasonable to include probesets found to have a
fold change >2 by RMA and confirmed by MAS5, even if
these data are flagged consistently unreliable by detection
call.
Both the MAS5.0 expression summary and detection call-
ing algorithms have been criticized, not only for their
poor performance on the Latin square data described
above, but also for the lack of statistical justification
underpinning them. Indeed, the expression summary
algorithm relies on a relatively ad hoc treatment of situa-
tions where PM probes are of lower intensity than their
MM counterparts. It is interesting, therefore, that despite
these reservations, both algorithms perform well in prac-
tice. This underlines the importance of using real, repre-
sentative datasets to assess the performance of different
algorithms.
Finally, a feature of the MAS5.0 algorithm is its low com-
putational requirements. MAS5.0 considers data on a per-
array basis, placing much lower demands on memory
than other approaches that must access the entire dataset
at once. As microarray datasets are assembled that contain
thousands of arrays, computationally frugal approaches
such as MAS5.0 become increasingly appealing. These
data provide evidence that such advantages may not have
to be taken at the expense of biological precision.
Methods
Data analysis
All analyses were performed using BioConductor [27].
RMA, GCRMA, MAS5 data were produced using the
implementations found in the 'affy' [28], 'gcrma' [8] and
'simpleaffy' [29] BioConductor packages. MAS5 expres-
sion calls were generated using the simpleaffy implemen-
tation of [1], detection calls with the simpleaffy
implementation of [9]. Unless otherwise stated, alpha1
and alpha2 values were 0.05 and 0.065 respectively, the
default values for these arrays. All MAS5 data were scaled
to a TGT (Target Intensity) of 100. RMA and GCRMA were
run using default settings; GCRMA was computed using
the full model, making use of MM probes. Kappa coeffi-
cients were generated using the 'concord' package in R.
Pearson and uncentered Pearson correlation coefficients
were calculated in R in the usual way.
Data sets
Cell line comparison data
Expression data were generated by hybridizing RNA taken
from MCF7 and MCF10A human cell lines to Affymetrix
HGU133Plus2 microarrays. The experiment was per-
formed in triplicate to generate three replicates for each
cell line. Full details of the protocols and sample genera-
tion can be found in the supplementary data [see addi-
tional file 3].
Latin square data
RNA was produced by adding varying quantities of 16
known transcripts to a uniform RNA background taken
from a common reference pool. The resultant RNA mix-
tures were used to hybridize a series of microarrays, result-
ing in a dataset in which the concentration of each of the
spikes was known for each of the samples. Full details of
the design can be found in [4].
Real time PCR
Quantitative PCR assays were designed to detect the
Affymetrix target sequences for the selected probe sets.
Candidates for validation were selected (see figure 1) by
eliminating all 'non-standard' probesets (i.e. any that
have ids not defined by '* [0–9]_at'). Probesets were
selected to represent PP, PA and AA sets, and were chosen
across a range of fold-changes. The PA and AA-RMA
probesets with the largest fold changes were selected
(MAS5 or RMA, respectively). AA and PP probesets were
chosen to represent a range of fold changes by defining a
set of thresholds (2, 3, 4, 5, 6 fold) and selecting the
probesets adjacent to these. Note that a set of controls
were also selected to represent genes with 0 fold change –
see below. Thus probeset selection was not motivated by
any prior knowledge or biological hypothesis. All PP
probesets were called Present on all arrays, AA probesets
were flagged Absent on at least one sample in each cellBMC Bioinformatics 2007, 8:273 http://www.biomedcentral.com/1471-2105/8/273
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line and PA probesets were called Present in all three
members of one of the cell lines and Absent in at least one
member of the other cell line. Probesets from this group
were selected to have large fold changes in MAS5.0 but
RMA fold-changes < log2(2). This approach to filtering is
similar to that described in [25]. All AA-RMA probesets
were flagged AA but had an RMA fold-change > 2.
Probesets from this group with the biggest RMA fold
change were selected.
qPCR assays were designed using the Exiqon Human Uni-
versal Probe Library system. Out of an initial pool of 50
selected transcripts there were 38 for which the Probe
Library system was able to design assays. This high fail rate
was due to limiting assays to the Affymetrix probe selec-
tion regions for each transcript, which are generally
around 500 bp long. In some cases the Probe Library soft-
ware was unable to design an acceptable assay within such
a small region. Validation of these 38 assays led to a final
list of 35 which were used in the present study.
Labelled probes were purchased from the Exiqon Human
Universal Probe Library system [30] (Roche, Switzerland),
with amplification primers obtained from MWG (Ger-
many). RNA was extracted from MCF7 and MCF10a cell
lines using RNeasy reagents (Qiagen, Germany) and
reverse transcribed to cDNA using Taqman Reverse tran-
scription reagents (Applied Biosystems, USA) with ran-
dom hexamers as primers. Experiments were performed
on an ABI 7900 Real Time Sequence Detection System in
384 well format, using an Epmotion 5070 robot (Eppen-
dorf, Germany) for plate set up.
23 of the 78 assays came up after 40 cycles, which we con-
sidered to be below the limit of detection. For the pur-
poses of fold-change calculations, the values for these
samples were set to 40 cycles. Five potential control genes
were selected on the basis of being predicted as unchang-
ing in the array data by both algorithms and the most con-
sistent, Beta 2 Microglobulin (NM_004048), selected for
use as a normalisation assay. All reactions were performed
in triplicate and the whole experiment was repeated three
times. Data analysis was performed using the DDCt
method [31].
P/M/A filtering for AffyComp
The median expression level, I, for all A and M flagged val-
ues was calculated for each probeset. Filtering was per-
formed by setting the value for all samples flagged A/M to
the median value, I. Thus reliable probesets, consistently
flagged P, are left unchanged, whilst unreliable probesets,
consistently flagged A, have their values set to a constant
for that probeset. Their fold-changes therefore become
zero. Probesets changing from A to P will show a fold
change calculated between the value for the reliable (P)
sample and the median value, I. This approach to filtering
is necessary in order to analyze the data using Affycomp
(see below), since many of the metrics are sensitive to the
number of probesets in the analysis. It is not possible sim-
ply to remove probesets from the data. Instead, they must
be kept and their values adjusted to prevent their influenc-
ing on subsequent calculations. More sophisticated meth-
ods of filtering based on the replicate structure of the
experiment, are, of course possible, but this was felt to
lead to an unfair comparison against other algorithms
that make no use of this information.
AffyComp metrics
The metrics used by AffyComp are fully described in
[4,15]. A brief overview is useful here, however. All the
metrics are generated by processing the Latin square data-
set and comparing the fold-changes and signal intensities
produced by the test algorithm to the expected values,
given the known concentrations of the target transcripts
spiked into each of the arrays. The dataset was sufficiently
controlled that the fold-change for every transcript can be
predicted between every pair of samples. These data can
be used to investigate how good the test algorithm is at
reporting zero fold change for transcripts known to be
unchanging, for having a linear signal response, for
reporting the correct fold change for those that are known
to be changing, and for allowing differentially expressed
genes to be found by partitioning the dataset on fold
change. These are assessed in AffyComp using the follow-
ing metrics (reported in table 1): median SD provides a
measure of the standard deviation between replicates in
the dataset. A low median SD corresponds to an algorithm
that reports data with consistently low variance across the
range of expression levels. i.e. perfection is 0. Calculated
for unchanging probesets, the null log fc IQR and null
log fc 99.9%, report the interquartile range and 99.9th
percentile across the different arrays. For these, unchang-
ing probesets' signal strength shouldn't vary, thus perfec-
tion is 0. signal detect slope & signal detect R2: the data
were such that a plot of observed concentration against
expected concentration for the spike probes should have a
gradient of 1. The metrics report the slope and the R2 val-
ues from a simple linear model fitted to the data. Both
should ideally be 1. low, med, high slope: fitted slopes,
as before, but calculated for probesets targeting low,
medium and high concentration targets (the maximum
concentration < 4 pM, 4–32 pM and > 32 pM respec-
tively);  obs,-intended-fc-slope and Obs-(low)-int-fc-
slope: fold changes for the spike probesets were calculated
between pairs of arrays and compared to the expected fold
changes. A plot of these data should result in a graph with
a slope of 1. The slope was calculated for all probesets and
also restricted to those where the nominal concentration
<2 pM. Perfection is 1 for both metrics. low, med, high,
weighted avg AUC: Expression ratios for each probesetBMC Bioinformatics 2007, 8:273 http://www.biomedcentral.com/1471-2105/8/273
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were calculated for every pair of arrays and ordered by
their absolute log-ratio. Thus the number of True and
False Positives (TPs and FPs) above a given ratio can be
found for any pair of arrays, and consequently, the
number of TPs for a given FP rate. ROC curves were gener-
ated using these data up to a maximum of 100FPs, aver-
aged across all array-pairs and standardized to a
maximum height of 1. The ideal ROC curve has an area
under the curve (AUC) of 1 and corresponds to the situa-
tion where all TPs are found before a single FP is encoun-
tered. ROC curves are reported separately for the three
concentration groups described above, along with an
average weighted by the number of probesets in each
group. AFP, TFP call if fc > 2: the number of true and false
positives found simply by imposing a 2-fold threshold.
FC = 2, AFP, call if fc > 2: as before, but restricted to
probesets where the change is expected to be 2-fold.
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